Ischaemic preconditioning and outcomes after angioplasty: Effects of drug therapy

Drugs

Volumn 63, Issue 2, 2003, Pages 133-138

  Kato, Toru ^a   Yoshimoto, Nobuo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; AMINOPHYLLINE; BAMIFYLLINE; BRADYKININ; GLIBENCLAMIDE; GLIMEPIRIDE; GLYCERYL TRINITRATE; NALOXONE; NICORANDIL; NISOLDIPINE; PHENTOLAMINE; POTASSIUM CHANNEL;

ELECTROCARDIOGRAM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MOLECULAR MECHANICS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; SUDDEN DEATH; THORAX PAIN; VISUAL ANALOG SCALE;

ADENOSINE; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRADYKININ; DEATH, SUDDEN, CARDIAC; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; NICORANDIL; NITROGLYCERIN; POTASSIUM CHANNELS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, PURINERGIC P1;

ANGINA;

EID: 0037252043     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363020-00001     Document Type: Review

References (35)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36
2. Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990; 82: 2044-51
3. Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol 1992; 20: 578-86
4. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276-7
5. Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am J Physiol 1987; 255: H 1470-6
6. Airaksinen KEJ, Huikuri HV. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol 1997; 29: 1035-8
7. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res 1993; 27: 542-50
8. Sato T, O'Rourke B, Marban E. Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C. Circ Res 1998; 83: 110-4
9. Sato T, Sasaki N, O'Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35: 514-8
10. Marbar MS, Latchman DS, Walker JM, et al. Cardiac stress protein elevation 24 hours after brief ischemia or heart stress is associated with resistance to myocardial infarction. Circulation 1993; 88: 1264-72
11. Yellon DM, Baxter GF. A second window of protection or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 1995; 27: 1023-34
12. Kuzuya T, Hoshida S, Yamashita N, et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993; 72: 1293-9
13. Vegh A, Papp JG, Parrat JR. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20h after rapid cardiac pacing. Br J Pharmacol 1994; 113: 1081-2
14. Tosaki A, Cordis GA, Szerdahelyi P, et al. Effects of preconditioning on reperfusion arrhythmias, myocardial functions, formation of free radicals and ion shifts in isolated ischemic/reperfusion rat hearts. J Cardiovasc Pharmacol 1994; 23: 365-73
15. Okishige K, Yamashita K, Yoshinaga H, et al. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol 1996; 28: 70-3
16. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-5
17. Kloner RA, Yellon DM. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994; 24: 1133-42
18. Leesar MA, Stoddard M, Ahmed M, et al. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997; 95: 2500-7
19. Claeys MJ, Vrints CJ, Bosmans JM, et al. Aminophylline inhibits adaptation to ischaemia during angioplasty: role of adenosine in ischaemic preconditioning. Eur Heart J 1996; 17: 490-1
20. Tomai F, Crea F, Gaspardone A, et al. Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur Heart J 1996; 17: 846-53
21. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-6
22. Bijlstra PJ, Lutterman JA, Russel FGM, et al. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1996; 39: 1083-90
23. Auchampach JA, Cavero I, Gross GJ. Nicorandil attenuates myocardial dysfunction associated with transient ischemia by opening ATP-dependent potassium channels. J Cardiovasc Pharmacol 1992; 20: 765-71
24. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18J-24J
25. Markham A, Plosker GL, Goa KL. Nicorandil: an update review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60: 955-74
26. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 345-51
27. Kato T, Kamiyama T, Maruyama Y, et al. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J 2001; 141: 940-3
28. Sasaki N, Sato T, Ohler A, et al. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101: 439-45
29. Leesar MA, Stoddard M, Manchikalapudi S, et al. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 34: 639-50
30. Tomai F, Crea F, Gaspardone A, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999; 33: 1863-9
31. Wallbridge DR, Schulz R, Braun C, et al. No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine. J Mol Cell Cardiol 1996; 28: 1801-10
32. Ehring T, Heusch G. Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion? Cardiology 1997; 88 Suppl. 1: 3-14
33. Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103: 2935-41
34. Tomai F, Crea F, Gaspardone A, et al. Phentolamine prevents adaptation to ischemia during coronary angioplasty: role of alfa-adrenergic receptors in ischemic preconditioning. Circulation 1997; 96: 2171-7
35. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002; 359: 1269-74